Grid Therapeutics
Thomas L. Patz is the Chief Operating Officer of Grid Therapeutics. For over 20 years prior to joining Grid, Mr. Patz served as Executive Vice President, Strategic Initiatives, and General Counsel of MICROS Systems, Inc., a publicly traded software company. During his tenure at MICROS, Mr. Patz was instrumental in architecting over 30 transactions, including the sale of MICROS to Oracle Corporation in 2014 for $5.3 Billion.
Mr. Patz holds an AB degree from Brown University and a Juris Doctorate from the University of Virginia School of Law.
This person is not in any offices
Grid Therapeutics
Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD, and his team of scientists at Duke University Medical Center developing the first human-derived targeted immunotherapy for cancer.